Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Growth 2023-2029
The report requires updating with new data and is sent in 48 hours after order is placed.
Teduglutide (brand names Gattex in the US and Revestive in Europe) is a 33-membered polypeptide and glucagon-like peptide-2 (GLP-2) analog that is used for the treatment of short bowel syndrome.
LPI (LP Information)' newest research report, the “Glucagon-like Peptide-2 (GLP-2) Agonist Industry Forecast” looks at past sales and reviews total world Glucagon-like Peptide-2 (GLP-2) Agonist sales in 2022, providing a comprehensive analysis by region and market sector of projected Glucagon-like Peptide-2 (GLP-2) Agonist sales for 2023 through 2029. With Glucagon-like Peptide-2 (GLP-2) Agonist sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Glucagon-like Peptide-2 (GLP-2) Agonist industry.
This Insight Report provides a comprehensive analysis of the global Glucagon-like Peptide-2 (GLP-2) Agonist landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Glucagon-like Peptide-2 (GLP-2) Agonist portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Glucagon-like Peptide-2 (GLP-2) Agonist market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Glucagon-like Peptide-2 (GLP-2) Agonist and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Glucagon-like Peptide-2 (GLP-2) Agonist.
The global Glucagon-like Peptide-2 (GLP-2) Agonist market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Glucagon-like Peptide-2 (GLP-2) Agonist is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Glucagon-like Peptide-2 (GLP-2) Agonist is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Glucagon-like Peptide-2 (GLP-2) Agonist is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Glucagon-like Peptide-2 (GLP-2) Agonist players cover Takeda Pharmaceuticals. etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Glucagon-like Peptide-2 (GLP-2) Agonist market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
What is the 10-year outlook for the global Glucagon-like Peptide-2 (GLP-2) Agonist market?
What factors are driving Glucagon-like Peptide-2 (GLP-2) Agonist market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Glucagon-like Peptide-2 (GLP-2) Agonist market opportunities vary by end market size?
How does Glucagon-like Peptide-2 (GLP-2) Agonist break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Teduglutide (brand names Gattex in the US and Revestive in Europe) is a 33-membered polypeptide and glucagon-like peptide-2 (GLP-2) analog that is used for the treatment of short bowel syndrome.
LPI (LP Information)' newest research report, the “Glucagon-like Peptide-2 (GLP-2) Agonist Industry Forecast” looks at past sales and reviews total world Glucagon-like Peptide-2 (GLP-2) Agonist sales in 2022, providing a comprehensive analysis by region and market sector of projected Glucagon-like Peptide-2 (GLP-2) Agonist sales for 2023 through 2029. With Glucagon-like Peptide-2 (GLP-2) Agonist sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Glucagon-like Peptide-2 (GLP-2) Agonist industry.
This Insight Report provides a comprehensive analysis of the global Glucagon-like Peptide-2 (GLP-2) Agonist landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Glucagon-like Peptide-2 (GLP-2) Agonist portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Glucagon-like Peptide-2 (GLP-2) Agonist market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Glucagon-like Peptide-2 (GLP-2) Agonist and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Glucagon-like Peptide-2 (GLP-2) Agonist.
The global Glucagon-like Peptide-2 (GLP-2) Agonist market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Glucagon-like Peptide-2 (GLP-2) Agonist is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Glucagon-like Peptide-2 (GLP-2) Agonist is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Glucagon-like Peptide-2 (GLP-2) Agonist is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Glucagon-like Peptide-2 (GLP-2) Agonist players cover Takeda Pharmaceuticals. etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Glucagon-like Peptide-2 (GLP-2) Agonist market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
- Gattex
- Revestive
- Hospital
- Pharmacy
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Takeda Pharmaceuticals
What is the 10-year outlook for the global Glucagon-like Peptide-2 (GLP-2) Agonist market?
What factors are driving Glucagon-like Peptide-2 (GLP-2) Agonist market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Glucagon-like Peptide-2 (GLP-2) Agonist market opportunities vary by end market size?
How does Glucagon-like Peptide-2 (GLP-2) Agonist break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Glucagon-like Peptide-2 (GLP-2) Agonist by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Glucagon-like Peptide-2 (GLP-2) Agonist by Country/Region, 2018, 2022 & 2029
2.2 Glucagon-like Peptide-2 (GLP-2) Agonist Segment by Type
2.2.1 Gattex
2.2.2 Revestive
2.3 Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type
2.3.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Type (2018-2023)
2.3.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue and Market Share by Type (2018-2023)
2.3.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sale Price by Type (2018-2023)
2.4 Glucagon-like Peptide-2 (GLP-2) Agonist Segment by Application
2.4.1 Hospital
2.4.2 Pharmacy
2.4.3 Other
2.5 Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application
2.5.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sale Market Share by Application (2018-2023)
2.5.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue and Market Share by Application (2018-2023)
2.5.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sale Price by Application (2018-2023)
3 GLOBAL GLUCAGON-LIKE PEPTIDE-2 (GLP-2) AGONIST BY COMPANY
3.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Breakdown Data by Company
3.1.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Annual Sales by Company (2018-2023)
3.1.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Company (2018-2023)
3.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Annual Revenue by Company (2018-2023)
3.2.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Company (2018-2023)
3.2.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Company (2018-2023)
3.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sale Price by Company
3.4 Key Manufacturers Glucagon-like Peptide-2 (GLP-2) Agonist Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Glucagon-like Peptide-2 (GLP-2) Agonist Product Location Distribution
3.4.2 Players Glucagon-like Peptide-2 (GLP-2) Agonist Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR GLUCAGON-LIKE PEPTIDE-2 (GLP-2) AGONIST BY GEOGRAPHIC REGION
4.1 World Historic Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Geographic Region (2018-2023)
4.1.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country/Region (2018-2023)
4.2.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Annual Sales by Country/Region (2018-2023)
4.2.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Annual Revenue by Country/Region (2018-2023)
4.3 Americas Glucagon-like Peptide-2 (GLP-2) Agonist Sales Growth
4.4 APAC Glucagon-like Peptide-2 (GLP-2) Agonist Sales Growth
4.5 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Growth
4.6 Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales Growth
5 AMERICAS
5.1 Americas Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country
5.1.1 Americas Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2018-2023)
5.1.2 Americas Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2018-2023)
5.2 Americas Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type
5.3 Americas Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region
6.1.1 APAC Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region (2018-2023)
6.1.2 APAC Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Region (2018-2023)
6.2 APAC Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type
6.3 APAC Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Glucagon-like Peptide-2 (GLP-2) Agonist by Country
7.1.1 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2018-2023)
7.1.2 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2018-2023)
7.2 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type
7.3 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist by Country
8.1.1 Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2018-2023)
8.1.2 Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2018-2023)
8.2 Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type
8.3 Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Glucagon-like Peptide-2 (GLP-2) Agonist
10.3 Manufacturing Process Analysis of Glucagon-like Peptide-2 (GLP-2) Agonist
10.4 Industry Chain Structure of Glucagon-like Peptide-2 (GLP-2) Agonist
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Glucagon-like Peptide-2 (GLP-2) Agonist Distributors
11.3 Glucagon-like Peptide-2 (GLP-2) Agonist Customer
12 WORLD FORECAST REVIEW FOR GLUCAGON-LIKE PEPTIDE-2 (GLP-2) AGONIST BY GEOGRAPHIC REGION
12.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Size Forecast by Region
12.1.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Forecast by Region (2024-2029)
12.1.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Glucagon-like Peptide-2 (GLP-2) Agonist Forecast by Type
12.7 Global Glucagon-like Peptide-2 (GLP-2) Agonist Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Takeda Pharmaceuticals
13.1.1 Takeda Pharmaceuticals Company Information
13.1.2 Takeda Pharmaceuticals Glucagon-like Peptide-2 (GLP-2) Agonist Product Portfolios and Specifications
13.1.3 Takeda Pharmaceuticals Glucagon-like Peptide-2 (GLP-2) Agonist Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Takeda Pharmaceuticals Main Business Overview
13.1.5 Takeda Pharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Glucagon-like Peptide-2 (GLP-2) Agonist by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Glucagon-like Peptide-2 (GLP-2) Agonist by Country/Region, 2018, 2022 & 2029
2.2 Glucagon-like Peptide-2 (GLP-2) Agonist Segment by Type
2.2.1 Gattex
2.2.2 Revestive
2.3 Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type
2.3.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Type (2018-2023)
2.3.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue and Market Share by Type (2018-2023)
2.3.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sale Price by Type (2018-2023)
2.4 Glucagon-like Peptide-2 (GLP-2) Agonist Segment by Application
2.4.1 Hospital
2.4.2 Pharmacy
2.4.3 Other
2.5 Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application
2.5.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sale Market Share by Application (2018-2023)
2.5.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue and Market Share by Application (2018-2023)
2.5.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sale Price by Application (2018-2023)
3 GLOBAL GLUCAGON-LIKE PEPTIDE-2 (GLP-2) AGONIST BY COMPANY
3.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Breakdown Data by Company
3.1.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Annual Sales by Company (2018-2023)
3.1.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Company (2018-2023)
3.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Annual Revenue by Company (2018-2023)
3.2.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Company (2018-2023)
3.2.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Company (2018-2023)
3.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sale Price by Company
3.4 Key Manufacturers Glucagon-like Peptide-2 (GLP-2) Agonist Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Glucagon-like Peptide-2 (GLP-2) Agonist Product Location Distribution
3.4.2 Players Glucagon-like Peptide-2 (GLP-2) Agonist Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR GLUCAGON-LIKE PEPTIDE-2 (GLP-2) AGONIST BY GEOGRAPHIC REGION
4.1 World Historic Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Geographic Region (2018-2023)
4.1.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country/Region (2018-2023)
4.2.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Annual Sales by Country/Region (2018-2023)
4.2.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Annual Revenue by Country/Region (2018-2023)
4.3 Americas Glucagon-like Peptide-2 (GLP-2) Agonist Sales Growth
4.4 APAC Glucagon-like Peptide-2 (GLP-2) Agonist Sales Growth
4.5 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Growth
4.6 Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales Growth
5 AMERICAS
5.1 Americas Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country
5.1.1 Americas Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2018-2023)
5.1.2 Americas Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2018-2023)
5.2 Americas Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type
5.3 Americas Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region
6.1.1 APAC Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region (2018-2023)
6.1.2 APAC Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Region (2018-2023)
6.2 APAC Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type
6.3 APAC Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Glucagon-like Peptide-2 (GLP-2) Agonist by Country
7.1.1 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2018-2023)
7.1.2 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2018-2023)
7.2 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type
7.3 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist by Country
8.1.1 Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2018-2023)
8.1.2 Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2018-2023)
8.2 Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type
8.3 Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Glucagon-like Peptide-2 (GLP-2) Agonist
10.3 Manufacturing Process Analysis of Glucagon-like Peptide-2 (GLP-2) Agonist
10.4 Industry Chain Structure of Glucagon-like Peptide-2 (GLP-2) Agonist
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Glucagon-like Peptide-2 (GLP-2) Agonist Distributors
11.3 Glucagon-like Peptide-2 (GLP-2) Agonist Customer
12 WORLD FORECAST REVIEW FOR GLUCAGON-LIKE PEPTIDE-2 (GLP-2) AGONIST BY GEOGRAPHIC REGION
12.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Size Forecast by Region
12.1.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Forecast by Region (2024-2029)
12.1.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Glucagon-like Peptide-2 (GLP-2) Agonist Forecast by Type
12.7 Global Glucagon-like Peptide-2 (GLP-2) Agonist Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Takeda Pharmaceuticals
13.1.1 Takeda Pharmaceuticals Company Information
13.1.2 Takeda Pharmaceuticals Glucagon-like Peptide-2 (GLP-2) Agonist Product Portfolios and Specifications
13.1.3 Takeda Pharmaceuticals Glucagon-like Peptide-2 (GLP-2) Agonist Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Takeda Pharmaceuticals Main Business Overview
13.1.5 Takeda Pharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Glucagon-like Peptide-2 (GLP-2) Agonist Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Glucagon-like Peptide-2 (GLP-2) Agonist Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Gattex
Table 4. Major Players of Revestive
Table 5. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2018-2023) & (K Units)
Table 6. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Type (2018-2023)
Table 7. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Type (2018-2023) & ($ million)
Table 8. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Type (2018-2023)
Table 9. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sale Price by Type (2018-2023) & (USD/Unit)
Table 10. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2018-2023) & (K Units)
Table 11. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Application (2018-2023)
Table 12. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Application (2018-2023)
Table 13. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Application (2018-2023)
Table 14. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sale Price by Application (2018-2023) & (USD/Unit)
Table 15. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Company (2018-2023) & (K Units)
Table 16. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Company (2018-2023)
Table 17. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Company (2018-2023) ($ Millions)
Table 18. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Company (2018-2023)
Table 19. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sale Price by Company (2018-2023) & (USD/Unit)
Table 20. Key Manufacturers Glucagon-like Peptide-2 (GLP-2) Agonist Producing Area Distribution and Sales Area
Table 21. Players Glucagon-like Peptide-2 (GLP-2) Agonist Products Offered
Table 22. Glucagon-like Peptide-2 (GLP-2) Agonist Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Geographic Region (2018-2023) & (K Units)
Table 26. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share Geographic Region (2018-2023)
Table 27. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Geographic Region (2018-2023) & ($ millions)
Table 28. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Geographic Region (2018-2023)
Table 29. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country/Region (2018-2023) & (K Units)
Table 30. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Country/Region (2018-2023)
Table 31. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country/Region (2018-2023) & ($ millions)
Table 32. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Country/Region (2018-2023)
Table 33. Americas Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2018-2023) & (K Units)
Table 34. Americas Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Country (2018-2023)
Table 35. Americas Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2018-2023) & ($ Millions)
Table 36. Americas Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Country (2018-2023)
Table 37. Americas Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2018-2023) & (K Units)
Table 38. Americas Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2018-2023) & (K Units)
Table 39. APAC Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region (2018-2023) & (K Units)
Table 40. APAC Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Region (2018-2023)
Table 41. APAC Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Region (2018-2023) & ($ Millions)
Table 42. APAC Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Region (2018-2023)
Table 43. APAC Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2018-2023) & (K Units)
Table 44. APAC Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2018-2023) & (K Units)
Table 45. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2018-2023) & (K Units)
Table 46. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Country (2018-2023)
Table 47. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2018-2023) & ($ Millions)
Table 48. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Country (2018-2023)
Table 49. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2018-2023) & (K Units)
Table 50. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2018-2023) & (K Units)
Table 51. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2018-2023) & (K Units)
Table 52. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Country (2018-2023)
Table 53. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2018-2023) & ($ Millions)
Table 54. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Country (2018-2023)
Table 55. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2018-2023) & (K Units)
Table 56. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2018-2023) & (K Units)
Table 57. Key Market Drivers & Growth Opportunities of Glucagon-like Peptide-2 (GLP-2) Agonist
Table 58. Key Market Challenges & Risks of Glucagon-like Peptide-2 (GLP-2) Agonist
Table 59. Key Industry Trends of Glucagon-like Peptide-2 (GLP-2) Agonist
Table 60. Glucagon-like Peptide-2 (GLP-2) Agonist Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. Glucagon-like Peptide-2 (GLP-2) Agonist Distributors List
Table 63. Glucagon-like Peptide-2 (GLP-2) Agonist Customer List
Table 64. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Forecast by Region (2024-2029) & (K Units)
Table 65. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Forecast by Region (2024-2029) & ($ millions)
Table 66. Americas Glucagon-like Peptide-2 (GLP-2) Agonist Sales Forecast by Country (2024-2029) & (K Units)
Table 67. Americas Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Forecast by Country (2024-2029) & ($ millions)
Table 68. APAC Glucagon-like Peptide-2 (GLP-2) Agonist Sales Forecast by Region (2024-2029) & (K Units)
Table 69. APAC Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Forecast by Region (2024-2029) & ($ millions)
Table 70. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Forecast by Country (2024-2029) & (K Units)
Table 71. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Forecast by Country (2024-2029) & ($ millions)
Table 72. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales Forecast by Country (2024-2029) & (K Units)
Table 73. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Forecast by Type (2024-2029) & (K Units)
Table 75. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 76. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Forecast by Application (2024-2029) & (K Units)
Table 77. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 78. Takeda Pharmaceuticals Basic Information, Glucagon-like Peptide-2 (GLP-2) Agonist Manufacturing Base, Sales Area and Its Competitors
Table 79. Takeda Pharmaceuticals Glucagon-like Peptide-2 (GLP-2) Agonist Product Portfolios and Specifications
Table 80. Takeda Pharmaceuticals Glucagon-like Peptide-2 (GLP-2) Agonist Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 81. Takeda Pharmaceuticals Main Business
Table 82. Takeda Pharmaceuticals Latest Developments
Table 1. Glucagon-like Peptide-2 (GLP-2) Agonist Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Glucagon-like Peptide-2 (GLP-2) Agonist Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Gattex
Table 4. Major Players of Revestive
Table 5. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2018-2023) & (K Units)
Table 6. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Type (2018-2023)
Table 7. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Type (2018-2023) & ($ million)
Table 8. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Type (2018-2023)
Table 9. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sale Price by Type (2018-2023) & (USD/Unit)
Table 10. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2018-2023) & (K Units)
Table 11. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Application (2018-2023)
Table 12. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Application (2018-2023)
Table 13. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Application (2018-2023)
Table 14. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sale Price by Application (2018-2023) & (USD/Unit)
Table 15. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Company (2018-2023) & (K Units)
Table 16. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Company (2018-2023)
Table 17. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Company (2018-2023) ($ Millions)
Table 18. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Company (2018-2023)
Table 19. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sale Price by Company (2018-2023) & (USD/Unit)
Table 20. Key Manufacturers Glucagon-like Peptide-2 (GLP-2) Agonist Producing Area Distribution and Sales Area
Table 21. Players Glucagon-like Peptide-2 (GLP-2) Agonist Products Offered
Table 22. Glucagon-like Peptide-2 (GLP-2) Agonist Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Geographic Region (2018-2023) & (K Units)
Table 26. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share Geographic Region (2018-2023)
Table 27. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Geographic Region (2018-2023) & ($ millions)
Table 28. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Geographic Region (2018-2023)
Table 29. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country/Region (2018-2023) & (K Units)
Table 30. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Country/Region (2018-2023)
Table 31. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country/Region (2018-2023) & ($ millions)
Table 32. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Country/Region (2018-2023)
Table 33. Americas Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2018-2023) & (K Units)
Table 34. Americas Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Country (2018-2023)
Table 35. Americas Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2018-2023) & ($ Millions)
Table 36. Americas Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Country (2018-2023)
Table 37. Americas Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2018-2023) & (K Units)
Table 38. Americas Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2018-2023) & (K Units)
Table 39. APAC Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region (2018-2023) & (K Units)
Table 40. APAC Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Region (2018-2023)
Table 41. APAC Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Region (2018-2023) & ($ Millions)
Table 42. APAC Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Region (2018-2023)
Table 43. APAC Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2018-2023) & (K Units)
Table 44. APAC Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2018-2023) & (K Units)
Table 45. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2018-2023) & (K Units)
Table 46. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Country (2018-2023)
Table 47. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2018-2023) & ($ Millions)
Table 48. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Country (2018-2023)
Table 49. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2018-2023) & (K Units)
Table 50. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2018-2023) & (K Units)
Table 51. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2018-2023) & (K Units)
Table 52. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Country (2018-2023)
Table 53. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2018-2023) & ($ Millions)
Table 54. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Country (2018-2023)
Table 55. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2018-2023) & (K Units)
Table 56. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2018-2023) & (K Units)
Table 57. Key Market Drivers & Growth Opportunities of Glucagon-like Peptide-2 (GLP-2) Agonist
Table 58. Key Market Challenges & Risks of Glucagon-like Peptide-2 (GLP-2) Agonist
Table 59. Key Industry Trends of Glucagon-like Peptide-2 (GLP-2) Agonist
Table 60. Glucagon-like Peptide-2 (GLP-2) Agonist Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. Glucagon-like Peptide-2 (GLP-2) Agonist Distributors List
Table 63. Glucagon-like Peptide-2 (GLP-2) Agonist Customer List
Table 64. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Forecast by Region (2024-2029) & (K Units)
Table 65. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Forecast by Region (2024-2029) & ($ millions)
Table 66. Americas Glucagon-like Peptide-2 (GLP-2) Agonist Sales Forecast by Country (2024-2029) & (K Units)
Table 67. Americas Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Forecast by Country (2024-2029) & ($ millions)
Table 68. APAC Glucagon-like Peptide-2 (GLP-2) Agonist Sales Forecast by Region (2024-2029) & (K Units)
Table 69. APAC Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Forecast by Region (2024-2029) & ($ millions)
Table 70. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Forecast by Country (2024-2029) & (K Units)
Table 71. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Forecast by Country (2024-2029) & ($ millions)
Table 72. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales Forecast by Country (2024-2029) & (K Units)
Table 73. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Forecast by Type (2024-2029) & (K Units)
Table 75. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 76. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Forecast by Application (2024-2029) & (K Units)
Table 77. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 78. Takeda Pharmaceuticals Basic Information, Glucagon-like Peptide-2 (GLP-2) Agonist Manufacturing Base, Sales Area and Its Competitors
Table 79. Takeda Pharmaceuticals Glucagon-like Peptide-2 (GLP-2) Agonist Product Portfolios and Specifications
Table 80. Takeda Pharmaceuticals Glucagon-like Peptide-2 (GLP-2) Agonist Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 81. Takeda Pharmaceuticals Main Business
Table 82. Takeda Pharmaceuticals Latest Developments
LIST OF FIGURES
Figure 1. Picture of Glucagon-like Peptide-2 (GLP-2) Agonist
Figure 2. Glucagon-like Peptide-2 (GLP-2) Agonist Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Gattex
Figure 10. Product Picture of Revestive
Figure 11. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Type in 2022
Figure 12. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Type (2018-2023)
Figure 13. Glucagon-like Peptide-2 (GLP-2) Agonist Consumed in Hospital
Figure 14. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market: Hospital (2018-2023) & (K Units)
Figure 15. Glucagon-like Peptide-2 (GLP-2) Agonist Consumed in Pharmacy
Figure 16. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market: Pharmacy (2018-2023) & (K Units)
Figure 17. Glucagon-like Peptide-2 (GLP-2) Agonist Consumed in Other
Figure 18. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market: Other (2018-2023) & (K Units)
Figure 19. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Application (2022)
Figure 20. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Application in 2022
Figure 21. Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market by Company in 2022 (K Units)
Figure 22. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Company in 2022
Figure 23. Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market by Company in 2022 ($ Million)
Figure 24. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Company in 2022
Figure 25. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Geographic Region (2018-2023)
Figure 26. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Geographic Region in 2022
Figure 27. Americas Glucagon-like Peptide-2 (GLP-2) Agonist Sales 2018-2023 (K Units)
Figure 28. Americas Glucagon-like Peptide-2 (GLP-2) Agonist Revenue 2018-2023 ($ Millions)
Figure 29. APAC Glucagon-like Peptide-2 (GLP-2) Agonist Sales 2018-2023 (K Units)
Figure 30. APAC Glucagon-like Peptide-2 (GLP-2) Agonist Revenue 2018-2023 ($ Millions)
Figure 31. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales 2018-2023 (K Units)
Figure 32. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Revenue 2018-2023 ($ Millions)
Figure 33. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales 2018-2023 (K Units)
Figure 34. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Revenue 2018-2023 ($ Millions)
Figure 35. Americas Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Country in 2022
Figure 36. Americas Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Country in 2022
Figure 37. Americas Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Type (2018-2023)
Figure 38. Americas Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Application (2018-2023)
Figure 39. United States Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 40. Canada Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 41. Mexico Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 42. Brazil Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 43. APAC Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Region in 2022
Figure 44. APAC Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Regions in 2022
Figure 45. APAC Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Type (2018-2023)
Figure 46. APAC Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Application (2018-2023)
Figure 47. China Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 48. Japan Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 49. South Korea Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 50. Southeast Asia Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 51. India Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 52. Australia Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 53. China Taiwan Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 54. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Country in 2022
Figure 55. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Country in 2022
Figure 56. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Type (2018-2023)
Figure 57. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Application (2018-2023)
Figure 58. Germany Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 59. France Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 60. UK Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 61. Italy Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 62. Russia Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 63. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Country in 2022
Figure 64. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Country in 2022
Figure 65. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Type (2018-2023)
Figure 66. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Application (2018-2023)
Figure 67. Egypt Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 68. South Africa Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 69. Israel Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 70. Turkey Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 71. GCC Country Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 72. Manufacturing Cost Structure Analysis of Glucagon-like Peptide-2 (GLP-2) Agonist in 2022
Figure 73. Manufacturing Process Analysis of Glucagon-like Peptide-2 (GLP-2) Agonist
Figure 74. Industry Chain Structure of Glucagon-like Peptide-2 (GLP-2) Agonist
Figure 75. Channels of Distribution
Figure 76. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Forecast by Region (2024-2029)
Figure 77. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share Forecast by Region (2024-2029)
Figure 78. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share Forecast by Type (2024-2029)
Figure 79. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share Forecast by Type (2024-2029)
Figure 80. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share Forecast by Application (2024-2029)
Figure 81. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share Forecast by Application (2024-2029)
Figure 1. Picture of Glucagon-like Peptide-2 (GLP-2) Agonist
Figure 2. Glucagon-like Peptide-2 (GLP-2) Agonist Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Gattex
Figure 10. Product Picture of Revestive
Figure 11. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Type in 2022
Figure 12. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Type (2018-2023)
Figure 13. Glucagon-like Peptide-2 (GLP-2) Agonist Consumed in Hospital
Figure 14. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market: Hospital (2018-2023) & (K Units)
Figure 15. Glucagon-like Peptide-2 (GLP-2) Agonist Consumed in Pharmacy
Figure 16. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market: Pharmacy (2018-2023) & (K Units)
Figure 17. Glucagon-like Peptide-2 (GLP-2) Agonist Consumed in Other
Figure 18. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market: Other (2018-2023) & (K Units)
Figure 19. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Application (2022)
Figure 20. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Application in 2022
Figure 21. Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market by Company in 2022 (K Units)
Figure 22. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Company in 2022
Figure 23. Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market by Company in 2022 ($ Million)
Figure 24. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Company in 2022
Figure 25. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Geographic Region (2018-2023)
Figure 26. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Geographic Region in 2022
Figure 27. Americas Glucagon-like Peptide-2 (GLP-2) Agonist Sales 2018-2023 (K Units)
Figure 28. Americas Glucagon-like Peptide-2 (GLP-2) Agonist Revenue 2018-2023 ($ Millions)
Figure 29. APAC Glucagon-like Peptide-2 (GLP-2) Agonist Sales 2018-2023 (K Units)
Figure 30. APAC Glucagon-like Peptide-2 (GLP-2) Agonist Revenue 2018-2023 ($ Millions)
Figure 31. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales 2018-2023 (K Units)
Figure 32. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Revenue 2018-2023 ($ Millions)
Figure 33. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales 2018-2023 (K Units)
Figure 34. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Revenue 2018-2023 ($ Millions)
Figure 35. Americas Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Country in 2022
Figure 36. Americas Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Country in 2022
Figure 37. Americas Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Type (2018-2023)
Figure 38. Americas Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Application (2018-2023)
Figure 39. United States Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 40. Canada Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 41. Mexico Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 42. Brazil Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 43. APAC Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Region in 2022
Figure 44. APAC Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Regions in 2022
Figure 45. APAC Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Type (2018-2023)
Figure 46. APAC Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Application (2018-2023)
Figure 47. China Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 48. Japan Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 49. South Korea Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 50. Southeast Asia Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 51. India Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 52. Australia Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 53. China Taiwan Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 54. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Country in 2022
Figure 55. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Country in 2022
Figure 56. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Type (2018-2023)
Figure 57. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Application (2018-2023)
Figure 58. Germany Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 59. France Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 60. UK Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 61. Italy Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 62. Russia Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 63. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Country in 2022
Figure 64. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Country in 2022
Figure 65. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Type (2018-2023)
Figure 66. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Application (2018-2023)
Figure 67. Egypt Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 68. South Africa Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 69. Israel Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 70. Turkey Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 71. GCC Country Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Growth 2018-2023 ($ Millions)
Figure 72. Manufacturing Cost Structure Analysis of Glucagon-like Peptide-2 (GLP-2) Agonist in 2022
Figure 73. Manufacturing Process Analysis of Glucagon-like Peptide-2 (GLP-2) Agonist
Figure 74. Industry Chain Structure of Glucagon-like Peptide-2 (GLP-2) Agonist
Figure 75. Channels of Distribution
Figure 76. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Forecast by Region (2024-2029)
Figure 77. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share Forecast by Region (2024-2029)
Figure 78. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share Forecast by Type (2024-2029)
Figure 79. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share Forecast by Type (2024-2029)
Figure 80. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share Forecast by Application (2024-2029)
Figure 81. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share Forecast by Application (2024-2029)
